Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 4/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415474 | 0.89 | ALDH1A1 (0.46) | FABP7FABP5ALDH1A1KMT2ATDP1 | |
| SCHEMBL12415475 | 0.88 | FABP7 (0.42) | FABP7FABP5ALDH1A1TSHRCA1 | |
| SCHEMBL12415458 | 0.86 | FABP7 (0.43) | FABP7FABP5ALDH1A1MAPK1KMT2A | |
| SCHEMBL12415476 | 0.86 | CA1 (0.41) | FABP7FABP5ALDH1A1KMT2ACA1 | |
| SCHEMBL15592928 | 0.84 | CPB1 (0.42) | FABP7FABP5ALDH1A1MAPK1KMT2A | |
| SCHEMBL25836272 | 0.79 | FABP7 (0.52) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL15080525 | 0.78 | FABP7 (0.58) | FABP7FABP5ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8694813 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8694818 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 | |
| SCHEMBL8694810 | 0.77 | FABP7 (0.50) | FABP7FABP5ALDH1A1HCAR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | FABP7 4747/4885FABP5 4476/4885ALDH1A1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.